コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ype and severity of cognitive deficits after traumatic brain injury.
2 ted deficits in long-term potentiation after traumatic brain injury.
3 related quality of life up to 10 years after traumatic brain injury.
4 d in-hospital care programmes for paediatric traumatic brain injury.
5 m Hg) for 72 h after the diagnosis of severe traumatic brain injury.
6 e cohort of patients with moderate-to-severe traumatic brain injury.
7 s and in asymptomatic men with no history of traumatic brain injury.
8 c evaluation in critically ill patients with traumatic brain injury.
9 smolar therapy is often used to treat severe traumatic brain injury.
10 type-specific responses in a mouse model of traumatic brain injury.
11 Cognitive impairment is common following traumatic brain injury.
12 tted to the emergency department with severe traumatic brain injury.
13 se controlled cortical impact (CCI) model of traumatic brain injury.
14 rognosis in patients with moderate or severe traumatic brain injury.
15 lzheimer's disease, Parkinson's disease, and traumatic brain injury.
16 that might occur in EDS patients after mild traumatic brain injury.
17 damage during brain tissue deformation from traumatic brain injury.
18 might be a valuable therapeutic target after traumatic brain injury.
19 ubjects and 35 patients with moderate/severe traumatic brain injury.
20 compliance with goal-directed therapy after traumatic brain injury.
21 pairment, posttraumatic stress disorder, and traumatic brain injury.
22 over 30 to 60 days, before and after induced traumatic brain injury.
23 matic brain injury and six (3%) had moderate traumatic brain injury.
24 rs of ferroptotic death were increased after traumatic brain injury.
25 (PEGASUS) programme in children with severe traumatic brain injury.
26 proteins characterize acute and chronic mild traumatic brain injury.
27 a 27% improvement in the slowing produced by traumatic brain injury.
28 terns for discriminating clinical outcome in traumatic brain injury.
29 Canadian provinces, specifically for severe traumatic brain injury.
30 teractions between four treatments following traumatic brain injury.
31 inuous variable (p = 0.07) for patients with traumatic brain injury.
32 are still considered the most lethal type of traumatic brain injury.
33 observed for younger patients and those with traumatic brain injury.
34 rs would improve cognitive performance after traumatic brain injury.
35 Consecutive patients with severe traumatic brain injury.
36 n underestimated therapeutic potential after traumatic brain injury.
37 arly improve physical outcome 6 months after traumatic brain injury.
38 a critical role in the management of severe traumatic brain injury.
39 oped coma with subsequent DOC after a severe traumatic brain injury.
40 ive ability, both of which are vulnerable to traumatic brain injury.
41 ce impairments in subjects who have had mild traumatic brain injuries.
42 ute neurological diseases such as stroke and traumatic brain injuries.
43 te deaths are now split between those due to traumatic brain injury (52%) and multiple organ dysfunct
44 cortical synapse loss resulting from diffuse traumatic brain injury, a highly prevalent connectional
46 6 yr within 1 wk after a sports-related mild traumatic brain injury (acute mTBI) ( n = 18), 3 mo or l
49 cluding ischemic stroke, hemorrhagic stroke, traumatic brain injury, Alzheimer's disease, and multipl
50 s in the chronic phase after moderate-severe traumatic brain injury and 19 healthy control subjects.
51 in 32 patients with isolated moderate-severe traumatic brain injury and 32 patients with isolated mil
54 Sp mice were immunosuppressed acutely after traumatic brain injury and could not produce interleukin
55 k, we present a finite element model of post-traumatic brain injury and decompressive craniectomy tha
56 eceptors attenuated cognitive deficits after traumatic brain injury and enhanced synaptic plasticity
57 e critically injured with a preponderance of traumatic brain injury and had a 7-fold higher DD level
58 ng the pathophysiology of mild blast-induced traumatic brain injury and identifying the physical forc
59 riety of conditions, such as stroke, sepsis, traumatic brain injury and neurodegenerative diseases.
61 ir and improvement of recovery after stroke, traumatic brain injury and other diseases in which neuro
63 ual to four patients with moderate or severe traumatic brain injury and reporting glial fibrillary ac
64 ion in models of stroke, multiple sclerosis, traumatic brain injury and seizure, each having profound
65 ASUS programme, of whom 193 (97%) had severe traumatic brain injury and six (3%) had moderate traumat
66 t develops following brain injuries, such as traumatic brain injury and stroke, and is often associat
67 e oxygenation levels in patients with severe traumatic brain injury and the feasibility of a Phase II
68 trographic seizures after moderate-to-severe traumatic brain injury and to correlate continuous elect
69 nduced and diabetic peripheral neuropathies, traumatic brain injury, and amyotrophic lateral sclerosi
71 ippocampal slices were prepared 1 week after traumatic brain injury, and long-term potentiation was s
72 eurological conditions, including infection, traumatic brain injury, and neurodegenerative diseases,
73 BBE, determine its alteration in response to traumatic brain injury, and test potential therapeutic t
74 to the pathogenesis of in vitro and in vivo traumatic brain injury, and whether inhibition of 15-lip
78 English, French, Spanish, or Portuguese with traumatic brain injury as the base trauma, clearly formu
80 ) 10 years and older with moderate or severe traumatic brain injury (Barell Matrix Type 1 classificat
81 Treatment of secondary injury after severe traumatic brain injury based on brain tissue oxygenation
83 that is commonly seen after moderate/severe traumatic brain injury but has been of uncertain aetiolo
84 ic predictors following a moderate or severe traumatic brain injury but their prognostic accuracy is
85 paminergic drugs can enhance cognition after traumatic brain injury, but individual responses are hig
86 mprove clinical outcomes in pediatric severe traumatic brain injury, but the evidence is extremely fr
88 ce suggests that a single moderate or severe traumatic brain injury can also induce progressive neuro
89 patients with a hypodopaminergic state after traumatic brain injury can help stratify the choice of c
91 ithin 4 hours of injury after nonpenetrating traumatic brain injury characterized by Glasgow Coma Sca
92 in injury and 32 patients with isolated mild traumatic brain injury (comparison group) was assessed w
95 ically, impairments in these abilities after traumatic brain injury correlate in a dissociable manner
96 ma exposure, comorbid depression, history of traumatic brain injury, current alcohol abuse or depende
97 iety of neuropsychiatric disorders including traumatic brain injury, demyelinating disease, Alzheimer
100 ts with Alzheimer's disease, and people with traumatic brain injury exert less cognitive control duri
102 tion into the hippocampus of adult mice with traumatic brain injury, functionally integrate as mature
104 nsecutive children (age < 18 yr) with severe traumatic brain injury (Glasgow Coma Scale </= 8; intrac
105 y useful for the diagnosis and management of traumatic brain injury, glaucoma and hypertension, respe
106 xygenation and poor outcome following severe traumatic brain injury has been reported in observationa
107 34%) than those >=65 (ICC = 5 to 6%) and for traumatic brain injury (ICC = 5 to 13%) than other injur
108 traumatic microbleeds in patients with acute traumatic brain injury; (ii) determine whether appearanc
112 iratory infections in the postacute phase of traumatic brain injury impede optimal recovery and contr
113 quantify benefits of hypothermia therapy for traumatic brain injuries in adults and children by analy
114 a is likely a beneficial treatment following traumatic brain injuries in adults but cannot be recomme
117 asonable animal-on-a-chip model for inducing traumatic brain injury in an animal, producing significa
121 le the mechanisms underlying repetitive mild traumatic brain injury-induced neurodegeneration are unk
122 novel targets for pharmacologic treatment of traumatic brain injury-induced persistent cognitive defi
123 Cohorts were matched for age, hypotension, traumatic brain injury, injury mechanism, and need for e
130 cranial direct current stimulation following traumatic brain injury is dependent on white matter dama
131 Continuous assessment of physiology after traumatic brain injury is essential to prevent secondary
134 nogenesis, stroke, intracerebral hemorrhage, traumatic brain injury, ischemia-reperfusion injury, and
136 that respiratory infections even late after traumatic brain injury may pose a more serious threat th
137 gest that effective goal-directed therapy in traumatic brain injury may provide an opportunity to imp
138 t 3 days post-injury, S. pneumoniae-infected traumatic brain injury mice (TBI + Sp) had a 25% mortali
140 appropriate treatment of children with mild traumatic brain injury (mTBI) and intracranial injury (I
143 rs with and without a recent history of mild traumatic brain injury (mTBI) on deployment were evaluat
144 showed previously in C57BL/6J mice that mild traumatic brain injury (mTBI) transiently induced bone f
149 experimental results which show that a mild traumatic brain injury (mTBI, often referred to as concu
150 Populations most frequently evaluated were traumatic brain injury (n = 96), general pediatric criti
151 such as chronic stress, protein misfolding, traumatic brain injury or other pathological mechanisms
152 eatment potential for patients on Earth with traumatic brain injury or other pathology leading to int
153 us served as risk factors for disparities in traumatic brain injury outcomes between undocumented imm
159 is suggest that early tracheostomy in severe traumatic brain injury patients contributes to a lower e
162 nsor imaging abnormalities in a cohort of 97 traumatic brain injury patients were also mapped at the
163 al blood pressure (ABP) measurements from 34 traumatic brain injury patients were applied to create a
164 nalyzed if decompressive craniectomy affects traumatic brain injury patients' quality of life in the
170 ribed glymphatic system has been linked with traumatic brain injury, prolonged wakefulness, and aging
171 Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (r = 0.51; p = 0.01) and Injury S
174 lished that chronic cognitive problems after traumatic brain injury relate to diffuse axonal injury a
176 ng outcomes for uninsured children following traumatic brain injury requires a greater understanding
177 co-morbidity and mortality are compounded by traumatic brain injury resulting from blunt trauma, blas
179 in animal models of alcoholism, depression, traumatic brain injury, schizophrenia, multiple sclerosi
184 acerebral hemorrhage, acute ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and pos
185 phalopathy (CTE) is associated with repeated traumatic brain injuries (TBI) and is characterized by c
187 ve management was higher in patients without traumatic brain injury (TBI) (35%, N = 679) compared to
188 5, p < 0.001) from unintentional trauma, and traumatic brain injury (TBI) (OR = 5.77, p < 0.001) and
190 with cognitive fatigue between persons with traumatic brain injury (TBI) and healthy controls (HCs).
191 icroglial activation occurs following severe traumatic brain injury (TBI) and is believed to contribu
192 ed expression of MMPs have been described in traumatic brain injury (TBI) and may contribute to addit
196 studies are required to better characterise traumatic brain injury (TBI) and to identify the most ef
197 mpairment is a key cause of disability after traumatic brain injury (TBI) but relationships with over
210 is an urgent priority, yet current models of traumatic brain injury (TBI) inadequately recapitulate t
214 nd cognitive deficits.SIGNIFICANCE STATEMENT Traumatic brain injury (TBI) is a debilitating neurologi
216 sis after diffuse TBI.SIGNIFICANCE STATEMENT Traumatic brain injury (TBI) is a leading cause of acqui
220 Chronic neurodegeneration in survivors of traumatic brain injury (TBI) is a major cause of morbidi
232 Identifying new lipid markers linked to traumatic brain injury (TBI) is of major importance in c
238 Cerebral autoregulatory dysfunction after traumatic brain injury (TBI) is strongly linked to poor
240 ry deficits after TBI.SIGNIFICANCE STATEMENT Traumatic brain injury (TBI) is the leading cause of dea
243 hnologies for the point-of-care diagnosis of traumatic brain injury (TBI) lack sensitivity, require s
245 Brain degeneration, including that caused by traumatic brain injury (TBI) often leads to severe bladd
246 sregulation of pathways directly involved in traumatic brain injury (TBI) pathogenesis and have been
247 of physical activity are common features in traumatic brain injury (TBI) patients that may contribut
249 etection of neuron-specific enolase (NSE), a traumatic brain injury (TBI) protein biomarker, in dilut
251 omplement (C) systems in the pathogenesis of traumatic brain injury (TBI) was investigated by quantif
252 osed as a universal pathological hallmark of traumatic brain injury (TBI) with molecular markers of a
253 nd injuries, e.g., in Parkinson's disease or traumatic brain injury (TBI), and hence it will be usefu
254 eater risk of Parkinson's disease (PD) after traumatic brain injury (TBI), but it is possible that th
255 g is a mainstay of therapy for children with traumatic brain injury (TBI), but its overall associatio
256 f acute and chronic pain are associated with traumatic brain injury (TBI), but mechanisms responsible
257 recirculation of blood flow to a limb after traumatic brain injury (TBI), can modify levels of patho
258 njuries, specifically long bone fracture and traumatic brain injury (TBI), frequently occur together.
260 PSH has predominantly been described after traumatic brain injury (TBI), in which it is associated
264 ngth and learning, is dysregulated following traumatic brain injury (TBI), suggesting that stimulatio
265 ncreasing proportion of patients with severe traumatic brain injury (TBI), yet clinical trials and ou
266 tion and reactive microglia are hallmarks of traumatic brain injury (TBI), yet whether these cells co
281 s and subsequent neuroinflammation following traumatic brain injury (TBI); however, the underlying me
282 ecific outcome measure (clinically important traumatic brain injury [TBI], need for neurological inte
283 thologies are glioblastoma multiforme (GBM), traumatic brain injuries (TBIs), multiple sclerosis (MS)
284 n addition to evaluation of therapeutics for traumatic brain injury, this hybrid microlens imaging me
285 microglia in models of stroke, infection and traumatic brain injury, though the exact role of the imm
286 nd over the first week after moderate-severe traumatic brain injury; transthoracic echocardiogram wit
287 We included children (aged <18 years) with traumatic brain injury (trauma mechanism and image findi
289 pared with insured pediatric patients with a traumatic brain injury, uninsured patients were in worse
290 treat diffuse axonal injury (DAI) caused by traumatic brain injury, using two different therapeutic
292 anatomic interfaces across all severities of traumatic brain injury, we combined computational, analy
294 optic nerve ultrasonography in patients with traumatic brain injury were 97% (95% CI, 92% to 99%), 86
295 atients (< 18 yr old) with a severe isolated traumatic brain injury were identified in the National T
297 e cognitive effects of methylphenidate after traumatic brain injury were only seen in patients with l